BD's Covera Vascular Stent Approved for Patients With End-Stage Renal Disease
March 14, 2019—BD (Becton, Dickinson and Company) has received FDA premarket approval of the Covera vascular covered stent for patients with end-stage renal disease who are on hemodialysis.
According to the company, the Covera device is approved in the United States for use in the treatment of stenoses in native (nonstented) fistulae. Covera was designed to address challenging lesions in the arteriovenous access circuit. It is available in both a flared and a straight configuration to allow for precise sizing and apposition to the vessel wall, and it includes an easy-to-use thumbwheel delivery system.